Caficrestat

Caficrestat (AT-001) is an orally active aldose reductase inhibitor. Caficrestat can be used in the study of diabetic cardiomyopathy[1][2].

Product Specifications

CAS Number

[1355612-71-3]

Product Name Alternative

AT-001; Aldose reductase-IN-1

UNSPSC

12352005

Target

Aldose Reductase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/caficrestat.html

Purity

99.74

Solubility

DMSO : ≥ 28 mg/mL

Smiles

O=C1C2=NC=CN=C2C(CC(O)=O)=NN1CC3=NC4=C(C=CC(C(F)(F)F)=C4)S3

Molecular Formula

C17H10F3N5O3S

Molecular Weight

421.35

References & Citations

[1]Yepuri G, Kancharla K, Perfetti R, Shendelman S, Wasmuth A, Ramasamy R. The aldose reductase inhibitors AT-001, AT-003 and AT-007 attenuate human keratinocyte senescence. Front Aging. 2024 Dec 17;5:1466281.|[2]Gopal K, et ak. Aldose reductase inhibition alleviates diabetic cardiomyopathy and is associated with a decrease in myocardial fatty acid oxidation. Cardiovasc Diabetol. 2023 Mar 28;22 (1) :73.